Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects

被引:0
|
作者
Willi Cawello
Seong R. Kim
Marina Braun
Jan-Peer Elshoff
Junji Ikeda
Tomoo Funaki
机构
[1] UCB Pharma,
[2] Otsuka Pharmaceutical Co. Ltd.,undefined
来源
关键词
Japanese Subject; Rotigotine; Caucasian Subject; Dopamine Receptor Agonist; Patch Application;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:95 / 105
页数:10
相关论文
共 50 条
  • [1] Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects
    Cawello, Willi
    Kim, Seong R.
    Braun, Marina
    Elshoff, Jan-Peer
    Ikeda, Junji
    Funaki, Tomoo
    CLINICAL DRUG INVESTIGATION, 2014, 34 (02) : 95 - 105
  • [2] Pharmacokinetics, safety and tolerability of rotigotine after trandermal patch administration in Japanese and Caucasian healthy subjects
    Cawello, W.
    Braun, M.
    Horstmann, R.
    Funaki, T.
    Tadayasu, Y.
    MOVEMENT DISORDERS, 2006, 21 : S547 - S548
  • [3] Pharmacokinetics, safety, and tolerability of rotigotine transdermal system in healthy Japanese and Caucasian subjects following multiple-dose administration
    Willi Cawello
    Seong Ryul Kim
    Marina Braun
    Jan-Peer Elshoff
    Takeuchi Masahiro
    Junji Ikeda
    Tomoo Funaki
    European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41 : 353 - 362
  • [4] Pharmacokinetics, safety, and tolerability of rotigotine transdermal system in healthy Japanese and Caucasian subjects following multiple-dose administration
    Cawello, Willi
    Kim, Seong Ryul
    Braun, Marina
    Elshoff, Jan-Peer
    Masahiro, Takeuchi
    Ikeda, Junji
    Funaki, Tomoo
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2016, 41 (04) : 353 - 362
  • [5] PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PONESIMOD IN JAPANESE AND CAUCASIAN HEALTHY SUBJECTS
    Reyes, M.
    Brossard, P.
    Dingemanse, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S93 - S94
  • [6] Multiple-dose applications of rotigotine transdermal patch to evaluate the pharmacokinetics, safety, and tolerability in healthy subjects.
    Kim, B. H.
    Lim, K. S.
    Kim, J. W.
    Kim, M. G.
    Kim, T. E.
    Chung, Y. J.
    Yu, K. S.
    Shin, S. G.
    Jang, I. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S25 - S26
  • [7] Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects
    Hiroyuki Oshima
    Takao Yamazaki
    Lauren Benner
    Takashi Miki
    Ingrid Michon
    Tomasz Wojtkowski
    Atsunori Kaibara
    Salim Mujais
    Clinical Drug Investigation, 2015, 35 : 375 - 384
  • [8] Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects
    Oshima, Hiroyuki
    Yamazaki, Takao
    Benner, Lauren
    Miki, Takashi
    Michon, Ingrid
    Wojtkowski, Tomasz
    Kaibara, Atsunori
    Mujais, Salim
    CLINICAL DRUG INVESTIGATION, 2015, 35 (06) : 375 - 384
  • [9] Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects
    Zhao, QY
    Brett, M
    Van Osselaer, N
    Huang, FL
    Raoult, A
    Van Peer, A
    Verhaeghe, T
    Hust, R
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (09): : 1002 - 1010
  • [10] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects
    Daniela Willen
    Wolfgang Uhl
    Peter Wolna
    Orestis Papasouliotis
    Özkan Yalkinoglu
    European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45 : 27 - 40